体内药代高通量筛选研究进展

Research Progress in in vivo Pharmacokinetics Screening

随着组合化学和高通量活性筛选技术的发展,大量的活性化合物被发现,而这些活性化合物要最终成为上市的药物必须具备合适的药代动力学特征,这就对这些活性化合物的药代属性进行筛选提出要求。因此,在新药研发领域迫切需要发展高通量的药代筛选技术。目前,这项研究主要从体外和体内两个方面着手开展,本文介绍了体内药代高通量筛选所必需的生物样品分析技术的发展近况和体内药代高通量筛选模型的研究进展。

With the development of combinatorial chemistry and high-throughput screening technology, large numbers of lead compounds with pharmacological activity can be delivered for final optimization. However, turning a chemical lead compound into an ideal marketable medicine requires a balance of potency, safety and pharmacokinetics. So it is imperative to develop high-throughput pharmacokinetic screening technology, including in vitro and in vivo models. This paper focuses on the progress in throughput of in vivo pharmacokinetic screening study.